[go: up one dir, main page]

CR11721A - USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY - Google Patents

USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY

Info

Publication number
CR11721A
CR11721A CR11721A CR11721A CR11721A CR 11721 A CR11721 A CR 11721A CR 11721 A CR11721 A CR 11721A CR 11721 A CR11721 A CR 11721A CR 11721 A CR11721 A CR 11721A
Authority
CR
Costa Rica
Prior art keywords
dronedarone
mortality
prevention
preparation
medicinal product
Prior art date
Application number
CR11721A
Other languages
Spanish (es)
Inventor
Christophe Gaudin
Nacéra Hamdani
Davide Radzik
Eickels Martin Van
Original Assignee
Sanofi Aventis
She Blends Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0802127A external-priority patent/FR2930148A1/en
Application filed by Sanofi Aventis, She Blends Holding B V filed Critical Sanofi Aventis
Publication of CR11721A publication Critical patent/CR11721A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de dronedarona o sales farmacéuticamente aceptables de la misma, para la preparación de un medicamento para uso en la prevención de la hospitalización cardiovascular o de la mortalidad.Use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or mortality.

CR11721A 2008-04-17 2010-10-08 USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY CR11721A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
FR0802127A FR2930148A1 (en) 2008-04-17 2008-04-17 Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease
US4599508P 2008-04-18 2008-04-18
US15161109P 2009-02-11 2009-02-11
US15162209P 2009-02-11 2009-02-11
EP09290095 2009-02-11
EP09290098 2009-02-11
US15995609P 2009-03-13 2009-03-13
US6025710P 2010-06-10 2010-06-10

Publications (1)

Publication Number Publication Date
CR11721A true CR11721A (en) 2011-02-04

Family

ID=43447898

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11721A CR11721A (en) 2008-04-17 2010-10-08 USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY

Country Status (2)

Country Link
CR (1) CR11721A (en)
UY (1) UY31767A (en)

Also Published As

Publication number Publication date
UY31767A (en) 2009-12-14

Similar Documents

Publication Publication Date Title
DOP2010000299A (en) USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
NI201000211A (en) DRONEDARONE FOR THE PREVENTION OF PERMANENT ATRIAL FIBRILLATION.
HK1259250A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives
CL2012000319A1 (en) Use of a pharmaceutical composition comprising treprostinil for the preparation of a medicament for the treatment or prevention of a condition associated with cystic fibrosis.
BRPI1009392A2 (en) "pharmaceutical formulation, and use of a pharmaceutically effective amount of a pharmaceutical formulation."
BRPI0815894A2 (en) PHARMACEUTICAL COMPOSITION, USE OF THE SAME, AND PHARMACEUTICALLY ACCEPTABLE SALTS OF A COMPOUND.
WO2012156296A8 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
AR082493A1 (en) FORMULATIONS BASED ON NALBUFINE, AND ITS USES
CY1121852T1 (en) FORMULATIONS AND METHODS OF PREPARING FORMULATIONS FOR USE IN COLON CLEANSING
ECSP11010811A (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF ICTUS OR TRANSITIONAL ISCHEMICAL ATTACK
EA200900958A1 (en) DRUG NEVIRAPIN PREPARATION
ECSP10010553A (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
UY31887A (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVERSION
BRPI0920878A2 (en) ksp161 inhibitor to increase apoptosis, its administration and its use.
ECSP10010540A (en) USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
UY31767A (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
AR081031A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY IN PA-HUNDREDS WHO HAVE A FIRST RECURRENCE OF HEADPHONES OR ALE-TEO HEADPHONES
AR084975A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY IN PATIENTS WITH ISOLATED HEADPHONES FIBRILATION
AR081392A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS OR DEATH OR CARDIOVASCULAR EVENTS IN PATIENTS WITH PERMANENT FIBRILATION
CL2009000920A1 (en) Use of dronedarone or a pharmaceutically acceptable salt to prepare a drug useful for the prevention of cardiovascular hospitalizations.
TN2010000454A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalisation or of mortatily
UA105513C2 (en) Glucosamine prolonged release dosage form
TR201005911A2 (en) A drug formulation with improved dissolution profile.
TR200805337A2 (en) New oral pharmaceutical formulations containing the active ingredient Valsartan
TH0801002717B (en) An anti-fatigue agent and an orally administered composition containing andrographolide as the active ingredient.